TNF and inflammatory bowel disease: Infliximab has improved health outcomes for patients with IBD through its invasive delivery method, IV infusion while other anti-TNF therapies and biologics for IBD: adalimumab, ustekinumab, golimumab, and vedolizumab can all be administrated subcutaneously [15–19].